<TEMPLATE>

LETTER OF ACCESS FOR APIMF

<date< th=""></date<>
<active :="" ingredient="" name="" pharmaceutical=""></active>
<apimf :="" address="" and="" holders="" name=""></apimf>
<active :="" ingredient="" manufacturing="" pharmaceutical="" site(s)=""></active>
<apimf :="" number="" version=""></apimf>
<open :="" part=""></open>
<closed :="" part=""></closed>
< {APIMF Holders Name}, hereby authorizes the relevant NAFDAC staff members and external experts to
refer to and review the above-mentioned APIMF (and subsequent versions) in support of application(s)
submitted by {Applicants Name/Address} for the following product>
< (FPP product generic name), (strength) and (dosage form) (NAFDAC- Assigned reference number if known)>
<the active="" aforementioned="" batch-to-<="" committed="" ensuring="" file="" holder="" ingredient="" is="" master="" p="" pharmaceutical="" to=""></the>
batch consistency and to informing {Applicants Name} and NAFDAC of any change in the Open or Closed parts
of the APIMF before any significant change is made to the site of manufacture, manufacturing procedure or
quality control specifications of the API. Except as permitted by NAFDAC guidelines relating to changes to
medicines, such changes will not be made to the API to be used in manufacture of the medicine destined to be
distributed in Nigeria before written approval is granted by NAFDAC.
It is understood that the consequences of failure to obtain approval for changes where approval is necessary
may include de-registration and recall of batches of medicines.>
<name &="" of="" officer="" responsible="" signature=""></name>
<designation></designation>

<Name and Address of APIMF Holder>